SNHG10: A Novel Long Non-coding RNA with Multifaceted Roles in Human Cancers.

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current pharmaceutical design Pub Date : 2025-03-05 DOI:10.2174/0113816128356231250212050707

Haodong He, Jingjie Yang, Yan Zhou, Lihan Chen, Chuyuan Liao, Ting Gong, Tongtong Li, Haoran Liu, Yunfei Pan, Pengbo Zhang, Xiaolan Li, Chengfu Yuan

{"title":"SNHG10: A Novel Long Non-coding RNA with Multifaceted Roles in Human Cancers.","authors":"Haodong He, Jingjie Yang, Yan Zhou, Lihan Chen, Chuyuan Liao, Ting Gong, Tongtong Li, Haoran Liu, Yunfei Pan, Pengbo Zhang, Xiaolan Li, Chengfu Yuan","doi":"10.2174/0113816128356231250212050707","DOIUrl":null,"url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs) are a type of RNA with a length of more than 200 nucleotides. They do not encode proteins but are crucial in regulating gene expression and affecting the malignant biological behavior of cancer. Small nucleolar RNA host gene 10 (SNHG10) is a novel lncRNA that plays a regulatory role in many malignant tumors. Several recent studies have shown that SNHG10 is aberrantly expressed in various forms of cancer. This instability is closely related to important tumorigenic processes, such as cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and chemotherapy resistance. SNHG10 has been reported to play a role through a variety of molecular mechanisms, including serving as a competing endogenous RNA (ceRNA), regulating epigenetic processes, and affecting immune responses and tumor microenvironment. Furthermore, SNHG10 is involved in metabolic reprogramming, immune evasion, and chromatin remodeling, highlighting its diverse roles in tumor biology. Due to the specificity and selectivity of its expression level, the potential of SNHG10 as a diagnostic biomarker and therapeutic target has attracted significant attention, and its correlation with the prognosis and treatment of various tumor types is of great significance. This review focuses on the biological function and molecular mechanism of SNHG10 and its relationship with various malignant tumors. In addition, this review highlights the potential of SNHG10 to improve precision oncology and develop novel cancer therapies by investigating its upstream regulators, downstream targets, and interactions with nuclear and cytoplasmic processes.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128356231250212050707","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Long non-coding RNAs (lncRNAs) are a type of RNA with a length of more than 200 nucleotides. They do not encode proteins but are crucial in regulating gene expression and affecting the malignant biological behavior of cancer. Small nucleolar RNA host gene 10 (SNHG10) is a novel lncRNA that plays a regulatory role in many malignant tumors. Several recent studies have shown that SNHG10 is aberrantly expressed in various forms of cancer. This instability is closely related to important tumorigenic processes, such as cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and chemotherapy resistance. SNHG10 has been reported to play a role through a variety of molecular mechanisms, including serving as a competing endogenous RNA (ceRNA), regulating epigenetic processes, and affecting immune responses and tumor microenvironment. Furthermore, SNHG10 is involved in metabolic reprogramming, immune evasion, and chromatin remodeling, highlighting its diverse roles in tumor biology. Due to the specificity and selectivity of its expression level, the potential of SNHG10 as a diagnostic biomarker and therapeutic target has attracted significant attention, and its correlation with the prognosis and treatment of various tumor types is of great significance. This review focuses on the biological function and molecular mechanism of SNHG10 and its relationship with various malignant tumors. In addition, this review highlights the potential of SNHG10 to improve precision oncology and develop novel cancer therapies by investigating its upstream regulators, downstream targets, and interactions with nuclear and cytoplasmic processes.

查看原文本刊更多论文

长非编码 RNA（lncRNA）是一种长度超过 200 个核苷酸的 RNA。它们不编码蛋白质，但在调控基因表达和影响癌症恶性生物学行为方面至关重要。小核RNA宿主基因10（SNHG10）是一种新型lncRNA，在许多恶性肿瘤中发挥调控作用。最近的一些研究表明，SNHG10在各种癌症中异常表达。这种不稳定性与细胞增殖、迁移、侵袭、上皮-间质转化（EMT）和化疗耐药性等重要的致瘤过程密切相关。据报道，SNHG10 通过多种分子机制发挥作用，包括作为竞争性内源性 RNA（ceRNA）、调节表观遗传过程、影响免疫反应和肿瘤微环境。此外，SNHG10 还参与了新陈代谢重编程、免疫逃避和染色质重塑，凸显了它在肿瘤生物学中的多种作用。由于其表达水平的特异性和选择性，SNHG10 作为诊断生物标志物和治疗靶点的潜力已引起人们的极大关注，其与各种肿瘤类型的预后和治疗的相关性也具有重要意义。本综述重点探讨 SNHG10 的生物学功能、分子机制及其与各种恶性肿瘤的关系。此外，本综述还通过研究 SNHG10 的上游调控因子、下游靶点以及与核和细胞质过程的相互作用，强调了 SNHG10 在提高肿瘤精准治疗和开发新型肿瘤疗法方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.